Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice

Jianteng Gu1,2†, Pamela Sun1†, Hailin Zhao1, Helena R Watts1, Robert D Sanders1, Niccolo Terrando3, Peiyuan Xia2*, Mervyn Maze3 and Daqing Ma1,4*

Abstract

Introduction: Acute kidney injury following surgery incurs significant mortality with no proven preventative therapy. We investigated whether the α2 adrenoceptor agonist dexmedetomidine (Dex) provides protection against ischemia-reperfusion induced kidney injury in vitro and in vivo.

Methods: In vitro, a stabilised cell line of human kidney proximal tubular cells (HK2) was exposed to culture medium deprived of oxygen and glucose. Dex decreased HK2 cell death in a dose-dependent manner, an effect attenuated by the α2 adrenoceptor antagonist atipamezole, and likely transduced by phosphatidylinositol 3-kinase (PI3K-Akt) signaling. In vivo C57BL/6J mice received Dex (25 μg/kg, intraperitoneal (i.p.)) 30 minutes before or after either bilateral renal pedicle clamping for 25 minutes or right renal pedicle clamping for 40 minutes and left nephrectomy.

Results: Pre- or post-treatment with Dex provided cytoprotection, improved tubular architecture and function following renal ischemia. Consistent with this cytoprotection, dexmedetomidine reduced plasma high-mobility group protein B1 (HMGB-1) elevation when given prior to or after kidney ischemia-reperfusion; pretreatment also decreased toll-like receptor 4 (TLR4) expression in tubular cells. Dex treatment provided long-term functional renoprotection, and even increased survival following nephrectomy.

Conclusions: Our data suggest that Dex likely activates cell survival signal pAKT via α2 adrenoceptors to reduce cell death and HMGB1 release and subsequently inhibits TLR4 signaling to provide reno-protection.
potent $\alpha_2$ adrenergic agonist with a remarkable binding specificity for the $\alpha_2$ adrenoceptor. Novel organoprotective properties of dexmedetomidine have been explored in the brain, heart and renal injury [18-21]. Indeed $\alpha_2$ adrenoceptors are distributed widely in the renal proximal, distal tubules and peri-tubular vasculature. Clinically $\alpha_2$ adrenoceptor agonists enhance urine flow rate and perioriental renal function [22,23]; however, the underlying molecular mechanisms remain unknown. Animal studies have suggested that $\alpha_2$ adrenoceptor agonists are renoprotective as a class; their mechanism largely revolving around modulating vasoreactivity [21,24,25]. Herein we report that dexmedetomidine protects against IRI to the kidney in mice and that the mechanism is due to a decrease in the level of renal cell death and suppression in the HMGB-1-TLR-4 inflammatory circuit.

Materials and methods

Cell line

A stabilised cell line of kidney cells (HK2), derived from adult human kidney proximal tubular cells, was used in our experiments (European Cell Culture Collection, Salisbury, UK). Cells were cultured in RPMI 1640 medium, 1% L-glutamine 100 nM, 1% penicillin-streptomycin 100 U/ml, 5% fetal calf serum (Gibco, Invitrogen Ltd, Paisley, UK) in a humidified atmosphere containing 5% CO$_2$. They were used soon after reaching 80% confluence.

Cell treatments

Cell injury was provoked by oxygen glucose deprivation (OGD) as we reported previously [26]. Briefly, OGD solution (116 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO$_4$, 1.0 mM NaH$_2$PO$_4$, 26 mM NaHCO$_3$ and 1.8 mM CaCl$_2$; pH 7.4) was bubbled through with pure nitrogen gas for 15 minutes using sterile Drechsel bottles to remove oxygen from the solution. Cells were washed sequentially with warmed HEPES buffer solution (120 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl$_2$, 1.8 mM CaCl$_2$, 15 mM anhydrous D-glucose and 20 mM HEPES) and warmed prepared OGD solution. The multi-well plates were then cultured with 1 ml of warmed OGD solution and incubated in air-tight gas chambers for the indicated period exposed to 95% nitrogen, 5% CO$_2$ at 37°C with or without dexmedetomidine (0.001 to 1 nM) (Orion Pharm UK Ltd, NewburyBerkshire, UK) +/− atipamezole (1 nM). After OGD treatment, cells were removed from the gas chamber, the OGD solution was replaced with warmed culture medium and placed in a humidified 5% CO$_2$ incubator at 37°C for 24 hrs. Cell viability was assessed using an 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Merck KGaA, Darmstadt, Germany) assay [26].

Other cell cohorts were treated with dexmedetomidine (0.1 nM) in the absence of OGD with or without the highly selective inhibitors of PI3-Akt, LY294002 (50 μM), and mitogen-activated protein kinase (MAPK), PD98059 (50 μM), respectively.

Animals

Ten-week-old male C57BL/6 mice weighing 20 to 25 g were housed in temperature and humidity-controlled cages with free access to sterile acidified water and irradiated food in a specific pathogen-free facility at Imperial College London. This study was approved by the ethics committee of Imperial College London and the UK Home Office (PPL: 70/6966) and all procedures were performed strictly under the United Kingdom Animals (Scientific Procedures) Act 1986.

Renal ischemia-reperfusion injury

Dexmedetomidine (25 μg/kg, i.p., based on the previous organ protection studies [19,27]) was administered 30 minutes before or immediately after renal ischemia-reperfusion injury (rIRI). One cohort was treated with the $\alpha_2$ adrenoceptor antagonist atipamezole (250 μg/kg, i.p. [19,27]) prior to the administration of dexmedetomidine. The naive group and the rIRI group served as negative and positive controls, respectively. The animals were sacrificed 24 hr after rIRI. Kidneys were harvested for H&E and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. All assessments were made by an investigator who was blinded to the experimental protocols. rIRI was induced either by bilateral renal pedicle clamping for 25 minutes to produce moderate renal injury, or by right renal pedicle clamping for 40 minutes and left nephrectomy to produce life-threatening renal injury, under 1.5% isoflurane surgical anesthesia. Sham-operated mice had dissection as above, but with no occlusion of the renal vessel. The intra-abdominal temperature was maintained at 36 ± 0.1°C with a heating pad which was servo-adjusted by a temperature controller (Engineering Inc, Stamford, CT, USA) throughout the experiment. For survival experiments, mice were monitored on a daily basis with a scoring assay based on body weight, activity and general appearance as reported previously. Any animals that scored > 7 were euthanized. All animals received 0.5 ml saline i.p. injection every 6 hrs for the first 24 hrs after experiments.

Immunoblot

Proteins were extracted from treated HK2 cells lines or frozen kidney samples by cell disruption in cell lysis buffer (New England Biolabs, Hitchin, Hertfordshire, UK) and sonication with an ultrasonic probe, followed by centrifugation at 10,000 g for 10 minutes at 4°C. The
supernatant was collected for Western blotting. Samples containing 30 μg of extracted protein, as determined by the Bradford protein assay (BioRad, Hemel Hempstead Hertfordshire, UK), were loaded on a NuPAGE 4 to 12% Bis-Tris gel (Invitrogen, Paisley, UK) for protein fractionation by electrophoresis and then electro-transferred to a nitrocellulose membrane (Hybond ECL; Amersham Biosciences, Little Chalfont, Buckinghamshire, UK). Blots were blocked with 5% non-fat dry milk in TBS (pH8.0, containing 0.1% Tween-20), and probed with appropriate antibodies (1:1,000 Akt, p-Akt and TLR4-all from followed Cell Signaling, Hitchin, Hertfordshire, UK; 1:100 TLR4- Santa Cruz, Wembley Middlesex, UK) by HRP-conjugated secondary antibodies (Cell Signaling) and visualisation with enhanced chemiluminescence (Cell Signaling). α-tubulin (1:2,000, Sigma, Dorset, UK) was used as internal control. Densitometry analysis were preformed and normalized with α-tubulin and then presented as percentage of control.

**Histologic score**

The sum score was calculated from the analysis of 10 cortical tubules/cross-section stained with H&E (10 sections/kidney) by using a modified scoring system [28]; 0, no damage. 1, mild damage: rounded epithelial cells and dilated tubular lumen; 2, moderate damage: flattened epithelial cells, loss of nuclear staining and substantially dilated lumen; 3, severe damage: destroyed tubules with no nuclear staining of epithelial cells.

**Immunohistochemistry**

The second l death of tubular epithelial cells was detected with in situ TUNEL assay Obiogene, Cambridge, UK) according to the manufacturer’s instructions. The fixed cryostat sections were washed with PBS and then treated with proteinase K (20 μg/ml) at room temperature for 15 minutes. For positive controls, sections were treated with nuclease (R&D System, Abingdon, UK) at 37°C for 15 minutes. The sections were then incubated with DiAminoBenzidine (DAB). The sum of the TUNEL+ cells in an objective grid from 10 areas of randomly selected renal cortex was counted under a 40 × objective lens by an investigator who was blinded to the experimental protocol.

The other fixed cryostat sections were incubated with 3% hydrogen peroxide for 30 minutes to quench endogenous peroxidase activity. Sections were blocked for 30 minutes in wash buffer phosphate buffered saline tween-20 containing 3% goat serum and then incubated at 4°C overnight with goat anti-mouse TLR-4 (Santa Cruz Biotechnology, Wembley, Middlesex, UK) diluted 1:250 in PBS and 1% goat serum. After washing with PBST, sections were incubated with biotinylated donkey anti-goat IgG (Santa Cruz) diluted 1:250 in PBS and then labelled with VectaStain Elite ABC solution (Vector Labs, Orton Southgate, Peterborough, UK). After further washes in PBS, staining was developed with DiAminoBenzidine (DAB) with nickel. Slides were washed in PBS buffer, dH2O and then in 100% ethanol for 10 minutes and xylene for 10 minutes before covered with cover glass for micrograph taken.

**Plasma creatinine, urea and HMGB1**

Both creatinine and urea were measured in 100 μl of plasma with an Olympus AU640 analyzer (Diamond Diagnostics, Watford, UK). Plasma HMGB1 was measured by ELISA according to the manufacturer’s instruction (IBL International GmbH, Hamburg, Germany).

**Statistical analysis**

Statistical comparison was by ANOVA followed by post hoc Student-Newman Keuls’s test where appropriate. Survival was analyzed by Kaplan-Meier test. A P < 0.05 was considered as statistically significant.

**Results**

**Dexmedetomidine confers in vitro protection via Akt activation**

To determine whether dexmedetomidine provides renoprotection in vitro, we exposed HK2 cells, a well-characterized human kidney proximal tubular cell line to oxygen and glucose deprivation (OGD), established to mimic the ischemic phase of renal ischemic reperfusion injury in our previous studies [26]. Cell viability analysis using MTT assay showed a time-dependent induction of injury with marked cell death (60% reduction in viability) occurring after 180-minutes OGD (0.39 ± 0.07 versus 1.0 ± 0.04 of control; P < 0.05) and was, therefore, used in subsequent experiments to determine the cytoprotective effects of dexmedetomidine (Figure 1A).

Incubating HK2 cells with dexmedetomidine (0.001 to 0.1 nM) before OGD exposure dose-dependently inhibited injury (Figure 1B). Treatment with 0.1 nM dexmedetomidine increased cell viability to 94% (from 0.35 ± 0.10 to 0.94 ± 0.12; P < 0.05), compared with the positive control (OGD). The cytoprotective effect of dexmedetomidine was abolished by co-treatment with the α2 adrenoceptor antagonist, atipamezole (1 nM), suggesting dexmedetomidine confers protection to renal epithelial cells via α2 adrenoceptor activation. Treatment of naive controls with either dexmedetomidine (0.1 nM) or atipamezole (1 nM) did not significantly decrease cell viability (0.8 ± 0.13 and 1.0 ± 0.25 respectively versus control). Therefore, neither
dexmedetomidine nor atipamezole were cytotoxic to HK2 cells.

Activation of the Akt pathway plays a key role in cytoprotective signaling and has been demonstrated to ameliorate renal injury in IRI mice [29]. To determine whether dexmedetomidine activates Akt, we measured phosphorylated Akt (pAkt) levels in HK2 cells incubated with media containing 0.1 nM dexmedetomidine for 5, 10, 20, 30 and 45 minutes (Figure 2A). Dexmedetomidine induced significant increases in pAkt at all time-points; whereas, total Akt protein levels were not altered. The magnitude of Akt phosphorylation peaked after 20 minutes (2.91 ± 0.54 versus 1.0 ± 0.25 of control; P < 0.01) and was used in subsequent experiments to identify upstream mediators of Akt activation. Atipamezole reduced, but could not completely abolish dexmedetomidine-induced phosphorylation of Akt, suggesting that pAkt activation may be partially dependent on α2 adrenoceptors (Figure 2B). LY294002 and PD98059 have been shown to act in vivo as highly selective inhibitors of PI3-Akt and mitogen-activated protein kinase (MAPK) cascades respectively. LY294002 (50 μM) rather than PD98059 (50 μM) completely abolished dexmedetomidine-induced activation of Akt (0.6 ± 0.2 versus 1.7 ± 0.2 of Dex only; P < 0.01), indicating that pAkt was generated in a PI3K-dependent manner.

**Dexmedetomidine reduces IRI pathological changes in vivo**

Next, we investigated whether dexmedetomidine provides protection against renal IRI in mice when the renal pedicle of both kidneys are clamped for 25 minutes. Twenty-four hours after IRI, kidneys and blood were harvested for histological assessment and for renal function (serum creatinine and urea), respectively. Histopathological assessment of cortical tubular damage was conducted by an investigator blinded to the experimental protocol. IRI significantly increased histopathological scoring (151 ± 45 versus 19 ± 9 of naive control; P < 0.01), as illustrated by severe tubular lumen dilatation, flattened renal epithelial cells and loss of nuclear staining (Figure 3C). Pre- and post-treatment with dexmedetomidine (25 μg/kg) resulted in a 53% and 38% reduction in damage (72 ± 15; P < 0.01 and 94 ± 19; P < 0.05) compared with IRI group, respectively (Figure 3G). Atipamazole (250 μg/kg) given prior to dexmedetomidine pre-treatment significantly inhibited the reno-protective action (142 ± 38; P < 0.01). Treatment of naïve animals with dexmedetomidine had no deleterious effects on kidney tissue (11 ± 9 versus 19 ± 9 of naïve control), in agreement with in vitro findings.

To evaluate kidney damage at the cellular level, we used terminal deoxynucleotidyl transferase-mediated digoxigenin-dideoxyuridine nick-end labeling (TUNEL) staining to detect dead tubular cells. IRI significantly increased TUNEL-positive cells (85.0 ± 28.5 versus 6.2 ± 5.3 of naive control, P < 0.01). Pre- and post-treatment with dexmedetomidine resulted in a 72% and 58% reduction in cell death (23.8 ± 7.5 and 35.2 ± 18.2; both P < 0.01), compared to IRI mice, respectively (Figure 4). Cellular reno-protection was abolished when dexmedetomidine pre-treatment was preceded by atipamazole (89.0 ± 14.3;
Molecular mechanisms of renoprotection afforded by dexmedetomidine (Dex) in vitro. Cultured human kidney proximal tubular cells (HK2) cells were treated with dexmedetomidine and the time course of phospho-a serine/threonine protein kinase (pAkt) expression in culture homogenised supernatant was assessed with western blot (A) and its effect was abolished with the highly selective inhibitor of PI3-Akt, LY294002 (LY) (50 μM), but not by α2 adrenoceptor antagonist, atipamazole (Atip) (1 nM) and mitogen-activated protein kinase (MAPK), PD98059 (PD) (50 μM) (B). Data are expressed as the percentage of control (mean ± SD; n = 4). *P < 0.05; **P < 0.01 vs control; +P < 0.05; ++P < 0.01 vs Dex.

In vivo renoprotection by dexmedetomidine (Dex) vs renal ischemia-reperfusion injury (IRI)-histology. Adult male mice were pretreated or post-treated with dexmedetomidine alone or in combination with α2 adrenoceptor antagonist, atipamazole (Atip) (1 nM) followed by clamping of the bilateral renal pedicle for 25 minutes. Renoprotection of Dex was assessed histologically (H&E staining). Representative microphotographs were taken from a naïve control (A), Dex alone (B), IRI alone (C), pre-Dex treatment (25 μg/kg) +IRI (D), post-Dex treatment (25 microgm/kg) + IRI (E) and Atip + pre-Dex+IRI (F). (G) Quantification of histological scoring following IRI in mice pretreated as above. Bar = 100 μm. Data are mean ± SD (n = 5). **P < 0.01 vs control. ++P < 0.01 vs IRI.
No difference in TUNEL staining was seen when dexmedetomidine was given to mice not subjected to renal injury (8.0 ± 2.3; NS versus naïve controls).

A similar pattern of changes were noted in renal function. After IRI, the plasma creatinine rose from 34.6 ± 2.2 to 81.8 ± 6.4 μM/L. Pre-treatment with dexmedetomidine was protective, with creatinine showing no significant difference from animals not subjected to renal injury. When dexmedetomidine pre-treatment was preceded by atipamazole, this abrogated the protective effect so that creatinine was significantly higher (85.8 ± 37.8; P < 0.01) than that seen in the uninjured animals (Figure 5A). Similarly, IRI-induced increase in plasma urea (from 5.4 ± 0.2 to 27.9 ± 5.0 mM/L) was significantly reduced following pre-treatment with dexmedetomidine (18.22 ± 4.3; P < 0.05), an effect that was completed abolished by atipamazole (30.0 ± 4.7; P < 0.01) (Figure 5B).

**Dexmedetomidine attenuates Toll-like Receptor 4 (TLR4) expression in tubular cells**

To investigate the molecular mechanisms of dexmedetomidine-induced renoprotection, we assessed toll-like receptor 4 (TLR4) expression in situ and its upstream mediator, high mobility group box-1 (HMGB1) nuclear protein in plasma. HMGB1 and TLR4 signaling play a pivotal role in the coordination of inflammatory responses in renal IRI [30,31]. There was no detectable staining when primary antibody was omitted (data not shown) while TLR4 expression was at very minimal level in the naïve control (Figure 6A). However, marked increases in renal TLR4 expression were detected in IRI mice using in situ immunostaining (Figure 6B) and Western blot (Figure 6E). Pre-treatment with dexmedetomidine resulted in a dramatic decrease in TLR4 expression (Figure 6C) to a level even lower than that of control (Figure 6E), which was effectively restored to even the higher level than that in the

---

Figure 4 *In vivo* reno-protection afforded by dexmedetomidine (Dex) vs renal ischemia-reperfusion injury (IRI)- TUNEL staining. Adult male mice were pretreated or post-treated with Dex alone or in combination with α₂ adrenoceptor antagonist, atipamazole (Atip) (1 nM) followed by clamping the bilateral renal pedicle for 25 minutes and the renoprotection of Dex was assessed with terminal deoxynucleotidyl transferase dUTP nick end (TUNEL) staining. Representative microphotographs taken from a naïve control (A), Dex alone (B), IRI alone (C), pre-Dex treatment (25 μg/kg) +IRI (D), post-Dex treatment (25 μg/kg) + IRI (E) and Atip + pre-Dex+IRI (F). (G) Quantification of TUNEL positive cell counting following IRI in mice pretreated as above. Bar = 100 μm. Data are mean ± SD (n = 5 to 6). *P < 0.05, **P < 0.01 vs control. + + P < 0.01 vs IRI.
control by atipamazole (Figure 6D). Similarly, plasma HMGB1 levels were dramatically elevated in IRI mice (from 25.9 ± 2.9 to 122.4 ± 40.3 pg/ml; \( P < 0.001 \)), compared to control. Pre- and post-treatment with dexmedetomidine significantly attenuated the rise in HMGB1 (58.1 ± 19.5 and 61.5 ± 28.3; both \( P < .01 \)) compared to IRI mice, respectively (Figure 6F). The protective effects of dexmedetomidine pre-treatment on HMGB1 upregulation were partially inhibited by atipamazole (61.5 ± 28.3; \( P < 0.05 \)) relative to IRI mice. Together, these findings suggest that

**Figure 5** *In vivo* renoprotection afforded by dexmedetomidine (Dex) vs renal ischemia-reperfusion injury (IRI). Adult male Mice were pretreated or post-treated with Dex alone or in combination with \( \alpha_2 \) adrenoceptor antagonist, atipamazole (Atip) (1 nM) and the renoprotection of Dex was assessed with plasma creatinine (A) and urea measurement (B). Data are mean ± SD (n = 5 to 6). * \( P < 0.05 \), ** \( P < 0.01 \) vs control. + \( P < 0.05 \), ++ \( P < 0.01 \) vs IRI.

**Figure 6** Anti-inflammatory effect afforded by dexmedetomidine (Dex) *in vivo*. Toll-like receptor 4 (TLR4) expression was assessed with *in situ* immunostaining and Western blot. Naive control (A); Renal ischemia-reperfusion injury (IRI) (B); Dex+IRI (C); Atip (atipamazole) + pre-Dex+IRI (D) and Western blot (E); (F) Plasma level of High-mobility group protein B1 (HMGB1). Bar = 100 μm. Data are mean ± SD (n = 4). ** \( P < 0.01 \) vs control. + \( P < 0.05 \), ++ \( P < 0.01 \) vs IRI.
HMGB1 and TLR4 pro-inflammatory signaling in renal IRI may be partially dependent on an α2 adrenoceptor-mediated mechanism. No change was seen in naïve mice treated with dexmedetomidine.

**Dexmedetomidine protects from renal failure**

To assess whether dexmedetomidine was also effective in the context of a more severe insult to renal function, we performed additional experiments in which the right renal pedicle was clamped for 40 minutes and the left kidney was removed. The mean value of plasma creatinine and urea rose more than seven-fold at 24 h after IRI (to 233.5 ± 34.1 μM/L and 62.1 ± 10.2 mM/L, respectively). Administration of dexmedetomidine either before or after IRI significantly attenuated the rise in creatinine and urea values (both \( P < 0.01 \)) relative to IRI controls (Figure 7A, B). Atipamezole treatment did not change creatinine and urea in IRI mice but significantly inhibited the renal protective effects of dexmedetomidine (\( P < 0.001 \), all comparisons). Long-term survival (no signs of illness at seven days) was noted in 70% and 60% of animals treated with dexmedetomidine before and after renal IRI. By contrast, animals not treated with dexmedetomidine or receiving atipamezole combined dexmedetomidine fared much worse. Within three days, 65% of these animals were dead (either spontaneously or killed because of severe ill health measured against previously reported predefined criteria [28] and no animals survived beyond five days after IRI (\( P < 0.001 \) versus pre- and post-dexmedetomidine groups; Figure 7C).

**Discussion**

Our work showed that dexmedetomidine induced a sustained up-regulation of phospho-Akt and protected against oxygen-glucose deprivation in a human kidney cell line; its effects were blocked by atipamezole. *In vivo,*

![Figure 7](http://ccforum.com/content/15/3/R153)

**Figure 7** Renal failure induced by ischemia-reperfusion prevented by dexmedetomidine (Dex). Mice received Dex before or after IRI and kidney injury was induced by clamping the right renal pedicle for 40 minutes while the contralateral kidney was removed. The animals were allowed for 24 hrs before functional measurements (A - Creatinine; B - Urea), or up to seven days for the long term Kaplan-Meier survival curve analysis (\( n = 10 \)) (C). Atip = atipamazole; IRI = Ischemia reperfusion injury. Data are mean ± SD (\( n = 5 \)). **\( P < 0.01 \) vs control. +\( P < 0.05 \), ++\( P < 0.01 \) vs IRI.
dexmedetomidine attenuated the HMGB-1/TLR-4 pathway, preserving tubular architecture and reducing cell death. Associated with the improved histological findings, the level of renal dysfunction was minimized and renal failure was prevented after severe IRI resulting in improved survival. The organ-protective effect was abolished with α2 adrenoceptor antagonist, indicating that dexmedetomidine acted in an α2 adrenoceptor dependent manner.

Our data demonstrated a significantly increased expression of phospho-Akt in cultured tubular cells after treatment with dexmedetomidine (Figure 2). This was blocked partially by an α2 adrenoceptor antagonist and significantly reduced by a PI3K inhibitor, indicating that the dexmedetomidine activates Akt via both α2 adrenoceptor dependent and independent-PI3K coupling. In summation, we consider it likely that the activation of PI3K-Akt is one of the survival cascades activated by dexmedetomidine to induce cytoprotection (Figure 1). The PI3K-Akt pathway promotes cell survival by phosphorylating the proapoptotic Bcl-2-associated death promotor (BAD) and up-regulating the expression of anti-apoptotic Bcl-2 and Bcl-xl [32], inhibiting the caspase-controlled intrinsic apoptotic pathway [33]. Consistent with our findings, dexmedetomidine has been shown to decrease the expression of pro-apoptotic factors such as caspase-3 [34] and Bax whilst increasing the expression of anti-apoptotic Bcl-2 and Mdm-2 [35] in the brain. Akt signaling has previously been shown to be critical to recovery from renal IRI injury and therefore, it can be concluded that dexmedetomidine protection may involve Akt signaling.

In addition to its cytoprotective effects, our studies demonstrated that dexmedetomidine suppressed the TLR-4 mediated inflammatory circuitry. Expression of TLR-4 has been shown to be triggered through endogenous ligands, including damage-associated molecular patterns (DAMPs) and cytokines. High mobility group box 1 (HMGB-1) is a potent DAMP released from dying cells during tissue ischemia. It binds to TLR-4 initiating downstream NF-κB signaling cascade [36] substantially augmenting the synthesis of pro-inflammatory cytokines such as TNF-α and IL-1β [37]. Recent work by Wu et al. [38] demonstrated that TLR4-deficient or the adaptor molecule myD88-deficient mice were protected from both kidney dysfunction and histological damage induced by renal IRI. Generation of pro-inflammatory cytokine (IL-6, IL-1β, and TNF-α) and chemokines (MIP-2 and MCP-1) was inhibited, together with a parallel decline of macrophage and neutrophil infiltration. Pre-treatment of dexmedetomidine resulted in almost complete attenuation of TLR-4 expression associated with decreased cell death of tubular epithelial cells. We propose that dexmedetomidine may have prevented the increased expression of TLR-4 by attenuating tissue injury (evidenced by lower systemic HMGB1 levels and reduced TUNEL staining) and through co-existent anti-inflammatory actions [39-41] (Figure 8). Herein, we did not further explore the well described anti-inflammatory effects of dexmedetomidine (beyond HMGB1 levels); however, dexmedetomidine reduces systemic levels of IL-6 and TNF-α following lipopolysaccharide infusion in rats [39] and following cardiac surgery [40] and sepsis in humans [42]. It is, therefore, plausible that the anti-inflammatory actions of dexmedetomidine contributed to the reduced TLR-4 expression following renal ischemia.

Figure 8 Putative mechanism of dexmedetomidine (Dex) renoprotection. Dexmedetomidine stimulates the α2 adrenoceptor (α2) to induce phosphoinositol-3-kinase (PI3K) phosphorylation of Akt (pAkt) and activation of the downstream cell survival signaling to block ischemia induced injury. Ischemia is denoted by the “flash” symbol. Improved cellular survival leads to reduced release of the damage-associated molecular pattern High-mobility group protein B1 (HMGB1). Reduced HMGB1 decreases the inflammatory drive that both increases Toll-like receptor 4 (TLR4) expression and activates the detrimental effect of TLR4 signaling in renal ischemia. Co-receptors for HMGB1 include TLRs and Interleukin-1 (IL-1) receptor; when HMGB1 binds to the ligand (for example, lipopolysaccharide or IL-1) this augments subsequent proinflammatory signaling. Therefore, dexmedetomidine acts proximally in the pathway (at the cytoprotective level) to prevent the elaboration of renal ischemic injury. ‘Lightening bolt’ denotes ischemia. ‘Square’ denotes HMGB1 co-receptor.
Our study showed a marked improvement in renal morphology and function with reduced nitrogenous waste accumulation following treatment of dexmedetomidine. This protection was attenuated by atipamezole, an α₂ adrenoreceptor antagonist, confirming dependence on α₂-adrenoceptor agonism. Similarly dexmedetomidine’s neuroprotective effect is mediated by α₂-adrenoceptor signaling [19]. Consistent with evidence from neuroprotection, our in vitro data suggest that the primary effect of dexmedetomidine is cytoprotection; nonetheless, in vivo it is likely that improved renal blood flow may have contributed to improved renal function and recovery from ischemia. Indeed modulation of vasoreactivity, through reduced sympathetic drive, has been shown to be an important mechanism of α₂ adrenoceptor agonist renoprotection [21,24,25]. In a model of radiocontrast nephropathy α₂-adrenoceptor activation with dexmedetomidine resulted in improved renal function, an effect attributable to improved renal blood flow [21]. However, α₂-adrenoceptor activation was not associated with cytoprotection from radiocontrast exposure in vitro [21] indicating that there are differing mechanisms of radiocontrast and ischemic injury in the kidney. The local responses to α₂-adrenoceptor activation in the kidney include vasodilatation [21], inhibition of renin release, increased glomerular filtration and increased secretion of sodium and water [43,44]. α₂-adrenoceptor agonists may preserve glomerular filtration by preventing reduced renal blood flow following reperfusion associated vasospasm. They may also provoke diuresis by opposing the activity of arginine vasopressin in the collecting duct as well reducing aquaporin expression [45]. In combination, cytoprotection, improved glomerular filtration and diuretic actions may have improved renal function following ischemic injury. 

α₂-adrenoceptor agonists have diverse utility in the perioperative period; their renoprotective qualities are complemented by their analgesic qualities that reduce the necessity of other analgesics. Reduced use of non-steroidal anti-inflammatory drugs and opioids may be of particular interest as non-steroidal anti-inflammatory drugs increase the risk of AKI and opioids accumulate in AKI. Furthermore, the hemodynamic control, cardioprotection and mild diuretic properties of α₂-adrenoceptor agonists may indirectly support renal function. We consider there are multiple reasons to consider a large prospective randomized controlled trial of the reno-protective qualities of α₂-adrenoceptor agonists.

Conclusions
AKI associated with ischemia-reperfusion injury is a significant contributor to morbidity and mortality in the perioperative period. Dexmedetomidine provides renoprotection against renal IRI whether given as a prophylactic or therapeutic measure. Our data complement preliminary clinical data showing that prophylactic clonidine treatment prevented renal dysfunction attributable to cardiac surgery and that dexmedetomidine improved renal function following thoracic surgery. If our data can be extrapolated to clinical settings, dexmedetomidine may prove protective against IRI associated acute renal failure.

Key messages
- Acute kidney injury following surgery significantly increases mortality with no proven preventative therapy.
- The α₂ adrenoceptor agonist dexmedetomidine has organoprotective properties.
- Dexmedetomidine activates cell survival signal pAKT via α₂ adrenoceptors to reduce cell death and HMGB1 release and subsequently inhibits TLR4 signaling to provide renoprotection.
- Dexmedetomidine may have both cytoprotective and anti-inflammatory effects to protect against renal injury following ischemia-reperfusion.
- If our data can be extrapolated to clinical settings, dexmedetomidine may prove protective against IRI associated acute renal failure.

Abbreviations
AKI: acute kidney injury; AKT: a serine/threonine protein kinase; DAMPs: damage-associated molecular patterns; Dex: dexmedetomidine; HK2: human kidney proximal tubular cells; HMGB-1: high-mobility group protein B1; IL interleukin; IRI: ischemia-reperfusion injury; MTT: 3-(4,5-Dimethyl-2-thiazoyl)-2,5-diphenyl -2H- tetrazolium bromide; NFκB: nuclear factor kappa-light-chain-enhancer of activated B cells; OGD: oxygen-glucose deprivation; PI3K: phosphatidylinositol 3-kinase; TLR-4: toll-like receptor 4; TNF-α: tumor necrosis factor α; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling.

Acknowledgements
This work was supported by a grant (RGFO9) from the European Society of Anesthesiology, Brussels, Belgium, to DM and a grant (2010ZX09401-306-1-3) from the State Science and Technology Commission, China to PX. JG was supported by a scholarship from the Chinese Scholarship Committee, Beijing, China.

Author details
1Department of Anaesthetics, Pain Medicine and Intensive Care, Faculty of Medicine, Imperial College London, Chelsea and Westminster Campus, 369 Fulham Rd, London SW10 9NH, UK. 2Department of Pharmacy, Southwest Hospital, Third Military Medical University, 30 Gaotanyan Road, Chongqing 400038, China. 3Department of Anesthesia and Perioperative Care, UCSF, 521 Parnassus Avenue, San Francisco, CA 94143, USA. 4Department of Anesthesiology, Hubei University of Medicine, Shiyuan, Huber 442000, P.R. China.

Authors’ contributions
JG carried out the in vivo and in vitro studies and drafted the manuscript. PS carried out the in vivo studies and drafted the manuscript. HZ, HRW and RDS drafted the manuscript. NI carried out ELISA measurements. PX and MM participated in the design of the study. DM designed studies, analysed data and drafted the manuscript. All authors read and approved the final manuscript.
Competing interests

MM has been a consultant for Abbott Laboratories, Abbott Park, IL, USA, to facilitate registration of dexmedetomidine in the United States. There is no conflict of interest involving the other authors.

Received: 18 March 2011 Revised: 4 May 2011 Accepted: 24 June 2011 Published: 24 June 2011

References

1. Perico N, Carradon J, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Transplantation 2006, 81:1841-1827.
2. Stafford-Smith M, Shaw A, Swaminathan M. Cardiac surgery and acute kidney injury: emerging concepts. Curr Opin Crit Care 2009, 15:498-502.
3. Koo DD, Welsh KL, Roake J, Morris P, Fuggle SW. Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion. Am J Pathol 1998, 153:557-566.
4. Kashyap VS, Cambria RP, Davison JK, 'Italien GJ. Failure of kidney function after thoracic surgery. Sladen RN: 24 2008, 32:174-179.
5. Arslan F, Keogh B, McGuirk P, Parker AE. Ischemia and reperfusion injury in liver transplantation. Transplant Proc 2005, 37:1635-1666.
6. Seer JW. Kidney dysfunction in the postoperative period. Br J Anaesth 2005, 95:20-32.
7. Borthwick E, Ferguson A. Perioperative acute kidney injury: risk factors, recognition, management, and outcomes. BMJ 2010, 341:c3385.
8. Engelberger L, Sun RM, Greason KL, Burkhardt HM, Sundt TM, Daly RC, Schaff HV. Deep hypothermic circulatory arrest is not a risk factor for acute kidney injury in thoracic aortic surgery. J Thorac Cardiovasc Surg 2011, 141:552-558.
9. Cerda J, Lameire N, Eggers P, Nannu S, Wang H, Bagga A, Levin A. Epidemiology of acute kidney injury. Clin J Am Soc Nephrol 2008, 3:881-886.
10. Schrier RW, Wang W, Poole B, Mitra A. Perioperative acute kidney injury: risk factors, recognition, management, and outcomes. Nat Rev Nephrol 2011, 7:326-336.
11. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2011, 114:5-14.
12. Carden DL, Granger DN. Pathophysiology of ischemia-reperfusion injury. J Pathol 2000, 190:255-266.
13. Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Marz M. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 2010, 6:244-255.
14. Arslan F, Keogh B, McGuirk P, Parker AE. TLR2 and TLR4 in ischemia and reperfusion injury. Exp Biol Med (Maywood) 2011, 236:174-179.
15. Hoste EA, Kellum JA. Ischemia/reperfusion injury via HIF-1alpha activation. Am J Physiol Renal Physiol 2009, 307:F173-720.
16. Nakata A, Takaoa M, Nishikawa M, Yuba M, Shibata Y, Okumura K, Kiatana K, Tsutsui H, Fuji K, Kobushi S, Okita M, Matsuura Y. Protective effect of 17beta-estradiol on ischemic acute renal failure through the PI3K/Akt/ERK pathway. Kidney Int 2008, 73:308-317.
17. Kline JR, Chang R, Davidson J, Bieniarz TR, Tung A. HMGB1: endogenous danger signal. Annu Rev Med 2008, 59:476-484.
18. Frankis NP, Lieb WR. Volatile general anaesthetics activate a novel neuronal K+-current. Nature 1988, 333:662-664.
19. Datta SR, Dudek H, Tao X, Masters S, Hiltz E, Hutzler P, Kochs G. The role of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 2003, 96:524-531.
20. O'Neill LA, Bowie AG. The family of five: TLR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 7:353-364.
21. Akta S, Takeda K, Kasho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Rev Immunol 2001, 1:675-680.
22. Xu H, Chen G, Wyburn KR, Yin J, Bertolino P, Alexander SI. Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphorylation in physiologic and ischemic conditions. Anesthesiology 2005, 103:869-977.
23. Engelhard K, Werner C, Eberspacher E, Bachl M, Blobner M, Martin J. The role of Toll-like receptors in ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2003, 125:550-552.
24. Loeve MJ, Lowry RS. Regulation of aquaporin-2 water channels in the kidney. Annu Rev Physiol 2000, 62:689-705.
25. Sanders RD, Maze M. Alpha2-Adrenergic agonists. Curr Opin Invest Drugs 2007, 8:25-33.
26. Ma D, Hossain M, Rajakumaraswamy A, Hossain M, Sun P, Hossain M, Ma D, Maze M. Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology 2009, 110:1077-1085.
27. Fabian M, Bischoff J, Leclercq B, Frere J, Muller R, Schulte H, Mergner M. Alpha2-adrenoceptor agonists. Drugs 1990, 41:25-33.
28. Leib WR. Volatile general anaesthetics activate a novel neuronal K+-current. Nature 1988, 333:662-664.
29. Datta SR, Dudek H, Tao X, Masters S, Hiltz E, Hutzler P, Kochs G. The role of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesthesiology 2003, 96:524-531.
30. Sanders RD, Hulting T, Zhao Y, Greenberg M. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
31. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.
32. Datta SR, Miyake Y. Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphorylation in physiologic and ischemic conditions. Anesthesiology 2005, 103:869-977.
33. Engelhard K, Werner C, Eberspacher E, Bachl M, Blobner M, Hiltz E, Hutzler P, Kochs G. The role of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 2003, 96:524-531.
34. O'Neill LA, Bowie AG. The family of five: TLR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 7:353-364.
35. Akta S, Takeda K, Kasho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Rev Immunol 2001, 1:675-680.
36. Xu H, Chen G, Wyburn KR, Yin J, Bertolino P, Alexander SI, Shariat AF, Chadban SJ. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007, 117:2847-2859.
37. Taniuchi T, Kidani Y, Kanakura H, Takeyama T, Yamamoto K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med 2004, 32:1522-1526.
38. Wern RM, Byrant A, Hall GM. Effects of dexmedetomidine on adrenergic function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth 2001, 86:650-656.
39. Sanders RD, Hulting T, Zhao Y, Greenberg M. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
40. Sanders RD, Hulting T, Zhao Y, Greenberg M. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
41. Memos D, Heimoglu S, Vatan J, Yandim T, Yusuf M, Sun P. Effects of midazolam and dexmedetomidine on inflammatory responses and gastric intramuscular pH to sepsis, in critically ill patients. Br J Anaesth 2007, 98:550-552.
42. Gentier R, Brown HC, Mitchell DH. Silvuka EH. Dexmedetomidine: a novel sedative-anaesthetic agent. Prog (Bayl Univ Med Cent) 2001, 14:13-21.
43. Philipp M, Brede M, Hein L. Physiological significance of alpha2-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 2002, 283:R287-R295.
44. Junaid A, Cul I, Penner SB, Smyth DD: Regulation of aquaporin-2 expression by the alpha2-adrenergic agonist clonidine in the rat. J Pharmacol Exp Ther 1999, 291:920-925.

Cite this article as: Gu et al. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Critical Care 2011 15:R153.